US FDA publishes 200 rejection letters in transparency push
View all comments(0)
July 10 (Reuters) - The U.S. Food and Drug Administration on Thursday published more than 200 of its so-called complete response letters to drugmakers, a significant move to increase transparency of the agency's work.
The published letters were issued in response to marketing applications of certain drugs or therapies submitted to the FDA between 2020 and 2024.
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Like
Recommended Articles
Featured Tools
Top News
April 2026 CPI Preview: Will Hot Inflation Crush Nasdaq, S&P 500 & NVDA? Explosive Market Reaction Guide

Cerebras Systems IPO 2026: Date, Price, Valuation, and Whether CBRS Is Worth Buying

'Big Short' Burry Doubles Down: Nvidia, Palantir Short Positions Double in Big Bet on AI Bubble Bursting

Is Micron the Next Nvidia? Why the 2026 "Memory Crunch" Makes MU Stock a Top AI Buy

U.S. April CPI Preview: Fed May Abandon Rate Cuts Until 2026?

Tradingkey






Comments (0)
Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.